| Date Filed | Type | Description |
| 09/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/17/2023 |
8-K
| Changes in Registrant's Certifying Accountant Interactive Data |
| 07/11/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/16/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/27/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 04/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/27/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/17/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
4/A
| MILBY RANDY (CEO) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Granted 515,127 options to buy
@ $0.39, valued at
$200.9k
|
|
| 02/14/2023 |
8-K
| Other Events Interactive Data |
| 02/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/04/2023 |
4
| MILBY RANDY (CEO) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Granted 621,795 options to buy
@ $0.39, valued at
$242.5k
|
|
| 10/28/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/18/2022 |
4
| Appajosyula Sireesh (Director) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Gifted 75,757 shares
@ $0
Gifted 7,576 shares
@ $0 |
|
| 06/23/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/21/2022 |
4
| MILBY RANDY (CEO) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Bought 500 shares
@ $0.7799, valued at
$390 |
|
| 06/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/07/2022 |
4
| MILBY RANDY (CEO) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Bought 234 shares
@ $0.6849, valued at
$160.3
Bought 100 shares
@ $0.6701, valued at
$67
Bought 66 shares
@ $0.6701, valued at
$44.2
Bought 500 shares
@ $0.6999, valued at
$350 |
|
| 06/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/19/2022 |
4
| MILBY RANDY (CEO) has filed a Form 4 on Hillstream BioPharma Inc.|
Txns:
| Exercised (in-or-at-the-money) 7,575 options to buy
@ $0.314, valued at
$2.4k
Exercised (in-or-at-the-money) 189,393 options to buy
@ $0.079, valued at
$15k
Exercised (in-or-at-the-money) 28,408 options to buy
@ $0.079, valued at
$2.2k
|
|
| 04/19/2022 |
3/A
| MILBY RANDY (CEO) has filed a Form 3/A on Hillstream BioPharma Inc. |
| 04/01/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 04/01/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|